1920 IMPACT OF MOLECULAR TARGETED DRUGS SUNITINIB AND SORAFENIB ON RENAL FUNCTION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

Hai-Liang Zhang,Ding-Wei Ye

DOI: https://doi.org/10.1016/j.juro.2013.02.2339

2013-01-01

Abstract:You have accessJournal of UrologyKidney Cancer: Advanced (II)1 Apr 20131920 IMPACT OF MOLECULAR TARGETED DRUGS SUNITINIB AND SORAFENIB ON RENAL FUNCTION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Hai-Liang Zhang and Ding-Wei Ye Hai-Liang ZhangHai-Liang Zhang Shanghai, China, People's Republic of More articles by this author and Ding-Wei YeDing-Wei Ye Shanghai, China, People's Republic of More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2339AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Molecular targeted drugs are first-line treatment for advanced renal cell carcinoma. The impact of these agents on renal function has not been well documented. This study was to compare the changes in renal function after sunitinib and sorafenib treatment in patients with metastatic renal cell carcinoma. METHODS From Dec 2007 to Dec 2011, a total of 221 patients with metastatic renal cell carcinoma were treated by sunitinib or sorafenib in our single center. The median follow-up time was 85 weeks (6 to 320 weeks). Serum creatinine levels, weight and age were record before and after the treatment for each patient's. In accordance with the formula to calculate the glomerular filtration rate (GFR) equals to [(140-age)íÁweight (kg)]/[0.818íÁScr (umol/L)]; Similarly, GFR two months (short-term) and 12 months (long-term) after treatment were also calculated. Degree of changes in GFR were evaluated according to CTCAE version 3.0. RESULTS Mean GFR before treatment, two months and 12 months after treatment were 75.44íÀ22.19ml/min, 73.93íÀ22.48ml/min and 73.98íÀ21.08ml/min, respectively. The initial GFR of 56 patients before treatment were less than 60 ml/min. In the 157 patients treated with sorafenib, GFR decline in three cases, remained unchanged in 83 cases, and improved in 71 cases 2 months after treatment. On the other hand, in the 64 patients receiving sunitinib, GFR declined in 22 cases, remained unchanged in 30 cases, and improved in 12 cases, statistically different between the two groups, p<0.001. After 12 months treatment, GFR decreased in 25 cases, remained unchanged in 60 cases, and improved 72 cases in sorafenib group; GFR decreased in 18 cases, unchanged in 29 cases, and improved in 17 cases in sunitinib group, still statistically different between the two groups, p=0.016. CONCLUSIONS Molecular targeted drugs have a certain impact on renal function in patients with metastatic renal cell carcinoma. At the beginning of treatment, sunitinib induces greater insufficiency in renal function than sorafenib, however, this difference in the impact on renal function will turn smaller after a longer treatment. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e787-e788 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hai-Liang Zhang Shanghai, China, People's Republic of More articles by this author Ding-Wei Ye Shanghai, China, People's Republic of More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...